Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.53 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.49 |
| ▸ | NOS2 | P35228 | 7/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 4/20 | 0.47 |
| ▸ | ARG2 | P78540 | 4/20 | 0.46 |
| ▸ | ARG1 | P05089 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL27550632 | 1.00 | OTC (0.53) | OTCGSRDDAH1NOS2NOS1 | |
| Arginine SCHEMBL18301526 | 0.98 | OTC (0.51) | OTCGSRDDAH1NOS2NOS1 | |
| Arginine SCHEMBL8041512 | 0.98 | OTC (0.51) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL43287 | 0.98 | GSR (0.52) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL27615800 | 0.98 | GSR (0.52) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL880728 | 0.98 | GSR (0.52) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL10071054 | 0.98 | GSR (0.52) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL28754154 | 0.98 | GSR (0.52) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL4221548 | 0.96 | GSR (0.50) | OTCGSRDDAH1NOS2NOS1 | |
| SCHEMBL4225043 | 0.96 | GSR (0.50) | OTCGSRDDAH1NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163958-B2 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use | NITROMED INC. (US) | 2007-01-16 | — | — | US | disclosed |
| EP-1525481-A2 | SELECTIVE BINDING AND ANALYSIS OF MACROMOLECULES: QUANTITATIVE ANALYSIS OF PROTEINS IN COMPLEX MIXTURES | Shimadzu Research Laboratory (Europe) Ltd. (GB) | 2005-04-27 | — | — | EP | disclosed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003102592-A2 | SELECTIVE BINDING AND ANALYSIS OF MACROMOLECULES: QUANTITATIVE ANALYSIS OF PROTEINS IN COMPLEX MIXTURES | SHIMADZU RESEARCH LABORATORY (EUROPE) LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NOS2, NOS1, NOS3 | OTC 813/4885GSR 107/4885DDAH1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.